Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | CCR6 | P51684 | 2/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 3/20 | 0.35 |
| ▸ | CA2 | P00918 | 3/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7371669 | 0.81 | KDM4E (0.40) | KDM4EALDH1A1L3MBTL1GRM5LMNA | |
| SCHEMBL7376200 | 0.81 | CA1 (0.55) | KDM4EALDH1A1L3MBTL1LMNAGAA | |
| SCHEMBL29401113 | 0.81 | ALDH1A1 (0.43) | KDM4EALDH1A1L3MBTL1CCR6LMNA | |
| Hydrochloric Acid SCHEMBL29291617 | 0.79 | KDM4E (0.39) | KDM4EALDH1A1L3MBTL1GRM5LMNA | |
| Ammonia Solution, Strong SCHEMBL8724525 | 0.79 | CA1 (0.53) | KDM4EALDH1A1L3MBTL1LMNAGAA | |
| SCHEMBL17168934 | 0.78 | ALDH1A1 (0.41) | TRPV4KDM4EALDH1A1L3MBTL1CCR6 | |
| SCHEMBL8724528 | 0.77 | ALDH1A1 (0.48) | KDM4EALDH1A1L3MBTL1CCR6LMNA | |
| SCHEMBL61854 | 0.73 | CA1 (0.55) | TRPV4KDM4EALDH1A1L3MBTL1GAA | |
| SCHEMBL15970403 | 0.72 | TRPV4 (0.43) | TRPV4GRM5CA1CA2EGLN2 | |
| SCHEMBL1465207 | 0.71 | NFE2L2 (0.42) | KDM4EALDH1A1L3MBTL1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4721737-A1 | USE OF PHARMACEUTICAL COMPOSITION COMPRISING COMPOUND HAVING BIS(AZANYLYLIDENE) SULFONYL STRUCTURE FOR TREATING ANEMIA-RELATED DISEASES | Scinnohub Pharmaceutical Co., Ltd. (CN) | 2026-04-08 | — | — | EP | disclosed |
| US-12410210-B2 | Neuroactive steroids and their methods of use | SAGE THERAPEUTICS, INC. (US) | 2025-09-09 | — | — | US | disclosed |
| US-20250154194-A1 | NEUROACTIVE STEROIDS AND THEIR METHODS OF USE | SAGE THERAPEUTICS, INC. | 2025-05-15 | — | — | US | disclosed |
| US-20250145635-A1 | COMPOUND CONTAINING BIS(AZANYLYLIDENE) SULFONYL STRUCTURE AND USE THEREOF IN MEDICINE | SCINNOHUB PHARMACEUTICAL CO., LTD. (CN) | 2025-05-08 | — | — | US | disclosed |
| US-12264177-B2 | Neuroactive steroids and their methods of use | SAGE THERAPEUTICS, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| US-12252509-B2 | Neuroactive steroids and their methods of use | SAGE THERAPEUTICS, INC. (US) | 2025-03-18 | — | — | US | disclosed |
| WO-2024245143-A1 | USE OF PHARMACEUTICAL COMPOSITION COMPRISING COMPOUND HAVING BIS(AZANYLYLIDENE) SULFONYL STRUCTURE FOR TREATING ANEMIA-RELATED DISEASES | 赛诺哈勃药业（成都）有限公司 | 2024-12-05 | — | — | WO | disclosed |
| EP-4455136-A1 | COMPOUND CONTAINING BIS(AZANYLYLIDENE) SULFONYL STRUCTURE AND USE THEREOF IN MEDICINE | Scinnohub Pharmaceutical Co., Ltd. (CN) | 2024-10-30 | — | — | EP | disclosed |
| US-20240343756-A1 | NEUROACTIVE STEROIDS AND THEIR METHODS OF USE | SAGE THERAPEUTICS, INC. | 2024-10-17 | — | — | US | disclosed |
| US-20240336648-A1 | NEUROACTIVE STEROIDS AND THEIR METHODS OF USE | SAGE THERAPEUTICS, INC. | 2024-10-10 | — | — | US | disclosed |
| EP-0909184-B1 | TARGETED DRUG DELIVERY USING SULFONAMIDE DERIVATIVES | UPJOHN CO (US) | 2003-09-17 | — | — | EP | disclosed |
| US-20030109555-A1 | TARGETED DRUG DELIVERY USING SULFONAMIDE DERIVATIVES | PHARMACIA & UPJ0HN COMPANY | 2003-06-12 | — | — | US | disclosed |
| EP-0758327-B1 | PYRANONE COMPOUNDS USEFUL TO TREAT RETROVIRAL INFECTIONS | UPJOHN CO (US) | 2003-04-09 | — | — | EP | disclosed |
| US-6169181-B1 | HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITORS | PHARMACIA & UPJOHN COMPANY | 2001-01-02 | — | — | US | disclosed |
| EP-0909184-A2 | TARGETED DRUG DELIVERY USING SULFONAMIDE DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 1999-04-21 | — | — | EP | disclosed |
| US-5852195-A | Pyranone compounds useful to treat retroviral infections | PHARMACIA & UPJOHN COMPANY (US) | 1998-12-22 | — | — | US | disclosed |
| WO-1998000173-A2 | TARGETED DRUG DELIVERY USING SULFONAMIDE DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 1998-01-08 | — | — | WO | disclosed |
| CN-1150424-A | Compounds for the treatment of retroviral infections | UPJOHN CO (US) | 1997-05-21 | — | — | CN | disclosed |
| EP-0758327-A1 | PYRANONE COMPOUNDS USEFUL TO TREAT RETROVIRAL INFECTIONS | PHARMACIA & UPJOHN COMPANY (US) | 1997-02-19 | — | — | EP | disclosed |
| WO-1995030670-A2 | PYRANONE COMPOUNDS USEFUL TO TREAT RETROVIRAL INFECTIONS | PHARMACIA & UPJOHN COMPANY (US) | 1995-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240336648-A1 | NEUROACTIVE STEROIDS AND THEIR METHODS OF USE | NR3C2, MC2R, NR3C1 | TRPV4 3578/4885KDM4E 2473/4885ALDH1A1 921/4885 |
| US-20250154194-A1 | NEUROACTIVE STEROIDS AND THEIR METHODS OF USE | NR3C2, MC2R, NR3C1 | TRPV4 3578/4885KDM4E 2473/4885ALDH1A1 921/4885 |
| US-12410210-B2 | Neuroactive steroids and their methods of use | NR3C2, MC2R, NR3C1 | TRPV4 3578/4885KDM4E 2473/4885ALDH1A1 921/4885 |
| US-20250145635-A1 | COMPOUND CONTAINING BIS(AZANYLYLIDENE) SULFONYL STRUCTURE AND USE THEREOF IN MEDICINE | BCL9, USP9X, BCL9L | TRPV4 4426/4885KDM4E 1211/4885ALDH1A1 2611/4885 |
| US-12252509-B2 | Neuroactive steroids and their methods of use | NR3C2, MC2R, NR3C1 | TRPV4 3578/4885KDM4E 2473/4885ALDH1A1 921/4885 |
| US-20240343756-A1 | NEUROACTIVE STEROIDS AND THEIR METHODS OF USE | NR3C2, MC2R, NR3C1 | TRPV4 3578/4885KDM4E 2463/4885ALDH1A1 931/4885 |
| US-12264177-B2 | Neuroactive steroids and their methods of use | NR3C2, MC2R, NR3C1 | TRPV4 3578/4885KDM4E 2473/4885ALDH1A1 921/4885 |
| US-20030109555-A1 | TARGETED DRUG DELIVERY USING SULFONAMIDE DERIVATIVES | GSTP1, GSTA2, GSTA1 | TRPV4 3909/4885KDM4E 3704/4885ALDH1A1 508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.